Canaccord Genuity reiterated their buy rating on shares of Edwards Lifesciences Corp. (NYSE:EW) in a research note released on Tuesday morning, AnalystRatingsNetwork.com reports. They currently have a $74.00 target price on the stock, down from their previous target price of $76.00.
Canaccord Genuity has also modified their ratings on a number of other healthcare stocks in the few days. The firm raised its price target on shares of Cyberonics Inc. from $70.00 to $73.00. They have a buy rating on that stock. Also, Canaccord Genuity reiterated its accumulate rating on shares of Endologix Inc.. They have a $22.00 price target on that stock.
In other Edwards Lifesciences Corp. news, VP Huimin Wang unloaded 4,650 shares of Edwards Lifesciences Corp. stock in a transaction dated Thursday, December 5th. The shares were sold at an average price of $64.65, for a total value of $300,622.50. Following the sale, the vice president now directly owns 31,337 shares in the company, valued at approximately $2,025,937. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
A number of other firms have also recently commented on EW. Analysts at Wells Fargo & Co. downgraded shares of Edwards Lifesciences Corp. from an outperform rating to a market perform rating in a research note to investors on Tuesday. Separately, analysts at CRT Capital initiated coverage on shares of Edwards Lifesciences Corp. in a research note to investors on Tuesday, November 26th. They set a fair value rating and a $72.00 price target on the stock. Finally, analysts at Deutsche Bank cut their price target on shares of Edwards Lifesciences Corp. from $73.00 to $61.00 in a research note to investors on Monday, November 4th. They now have a hold rating on the stock. Two research analysts have rated the stock with a sell rating, eleven have given a hold rating and eleven have issued a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and an average price target of $73.88.
Shares of Edwards Lifesciences Corp. (NYSE:EW) opened at 62.53 on Tuesday. Edwards Lifesciences Corp. has a 52 week low of $61.62 and a 52 week high of $94.98. The stock’s 50-day moving average is $66.24 and its 200-day moving average is $69.12. The company has a market cap of $6.841 billion and a price-to-earnings ratio of 17.78. Edwards Lifesciences Corp. also was the target of some unusual options trading on Monday. Investors purchased 9,271 put options on the stock. This is an increase of approximately 544% compared to the typical volume of 1,439 put options.
Edwards Lifesciences Corp. (NYSE:EW) last released its earnings data on Monday, October 28th. The company reported $0.68 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.66 by $0.02. The company had revenue of $496.00 million for the quarter, compared to the consensus estimate of $490.96 million. During the same quarter last year, the company posted $0.58 earnings per share. Edwards Lifesciences Corp.’s revenue was up 10.6% compared to the same quarter last year. Analysts expect that Edwards Lifesciences Corp. will post $3.05 EPS for the current fiscal year.
Edwards Lifesciences Corporation (NYSE:EW) is focused on technologies that treat structural heart disease and critically ill patients.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.